{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,29]],"date-time":"2025-10-29T09:55:34Z","timestamp":1761731734877,"version":"build-2065373602"},"reference-count":49,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,10,28]],"date-time":"2025-10-28T00:00:00Z","timestamp":1761609600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,10,28]],"date-time":"2025-10-28T00:00:00Z","timestamp":1761609600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/501100004731","name":"Natural Science Foundation of Zhejiang Province","doi-asserted-by":"publisher","award":["LQ24H310011"],"award-info":[{"award-number":["LQ24H310011"]}],"id":[{"id":"10.13039\/501100004731","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Pharmacol Toxicol"],"DOI":"10.1186\/s40360-025-01009-8","type":"journal-article","created":{"date-parts":[[2025,10,28]],"date-time":"2025-10-28T15:44:04Z","timestamp":1761666244000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Combination of B-AP15 and HSP90 inhibitor tanespimycin induces ROS-mediated cytotoxicity in human lung cancer cells"],"prefix":"10.1186","volume":"26","author":[{"given":"Wenying","family":"Fu","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hui","family":"Lu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ying","family":"Yan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chongchong","family":"Shu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chenxin","family":"Xu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yinghua","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yiqun","family":"Xia","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jundixia","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yunzhi","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Peng","family":"Zou","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ri","family":"Cui","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Daoyong","family":"Ni","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,10,28]]},"reference":[{"issue":"10299","key":"1009_CR1","doi-asserted-by":"publisher","first-page":"535","DOI":"10.1016\/S0140-6736(21)00312-3","volume":"398","author":"AA Thai","year":"2021","unstructured":"Thai AA, Solomon BJ, Sequist LV, Gainor JF, Heist RS. Lung cancer. Lancet. 2021;398(10299):535\u201354.","journal-title":"Lancet"},{"issue":"10454","key":"1009_CR2","doi-asserted-by":"publisher","first-page":"803","DOI":"10.1016\/S0140-6736(24)01029-8","volume":"404","author":"ML Meyer","year":"2024","unstructured":"Meyer ML, Fitzgerald BG, Paz-Ares L, Cappuzzo F, Janne PA, Peters S, Hirsch FR. New promises and challenges in the treatment of advanced non-small-cell lung cancer. Lancet. 2024;404(10454):803\u201322.","journal-title":"Lancet"},{"key":"1009_CR3","doi-asserted-by":"publisher","first-page":"n2363","DOI":"10.1136\/bmj.n2363","volume":"375","author":"M Miller","year":"2021","unstructured":"Miller M, Hanna N. Advances in systemic therapy for non-small cell lung cancer. BMJ. 2021;375:n2363.","journal-title":"BMJ"},{"issue":"1","key":"1009_CR4","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1016\/j.path.2019.11.002","volume":"13","author":"R Ruiz-Cordero","year":"2020","unstructured":"Ruiz-Cordero R, Devine WP. Targeted therapy and checkpoint immunotherapy in lung cancer. Surg Pathol Clin. 2020;13(1):17\u201333.","journal-title":"Surg Pathol Clin"},{"issue":"8","key":"1009_CR5","doi-asserted-by":"publisher","first-page":"1345","DOI":"10.1038\/s41591-021-01450-2","volume":"27","author":"M Wang","year":"2021","unstructured":"Wang M, Herbst RS, Boshoff C. Toward personalized treatment approaches for non-small-cell lung cancer. Nat Med. 2021;27(8):1345\u201356.","journal-title":"Nat Med"},{"key":"1009_CR6","doi-asserted-by":"crossref","unstructured":"Hoter A, El-Sabban ME, Naim HY. The HSP90 family: structure, regulation, function, and implications in health and disease. Int J Mol Sci 2018;19(9).","DOI":"10.3390\/ijms19092560"},{"issue":"2","key":"1009_CR7","doi-asserted-by":"publisher","first-page":"e470","DOI":"10.1002\/mco2.470","volume":"5","author":"H Wei","year":"2024","unstructured":"Wei H, Zhang Y, Jia Y, Chen X, Niu T, Chatterjee A, He P, Hou G. Heat shock protein 90: biological functions, diseases, and therapeutic targets. MedComm (2020). 2024;5(2):e470.","journal-title":"MedComm (2020)"},{"key":"1009_CR8","doi-asserted-by":"publisher","first-page":"176387","DOI":"10.1016\/j.ejphar.2024.176387","volume":"967","author":"Y Zhu","year":"2024","unstructured":"Zhu Y, Dai Z. HSP90: A promising target for NSCLC treatments. Eur J Pharmacol. 2024;967:176387.","journal-title":"Eur J Pharmacol"},{"key":"1009_CR9","doi-asserted-by":"publisher","first-page":"471","DOI":"10.1016\/B978-0-12-397927-8.00015-4","volume":"65","author":"K Jhaveri","year":"2012","unstructured":"Jhaveri K, Modi S. HSP90 inhibitors for cancer therapy and overcoming drug resistance. Adv Pharmacol. 2012;65:471\u2013517.","journal-title":"Adv Pharmacol"},{"issue":"15","key":"1009_CR10","doi-asserted-by":"publisher","first-page":"5132","DOI":"10.1158\/1078-0432.CCR-11-0072","volume":"17","author":"S Modi","year":"2011","unstructured":"Modi S, Stopeck A, Linden H, Solit D, Chandarlapaty S, Rosen N, D\u2019Andrea G, Dickler M, Moynahan ME, Sugarman S, et al. HSP90 Inhibition is effective in breast cancer: a phase II trial of tanespimycin (17-AAG) plus trastuzumab in patients with HER2-positive metastatic breast cancer progressing on trastuzumab. Clin Cancer Res. 2011;17(15):5132\u20139.","journal-title":"Clin Cancer Res"},{"issue":"5","key":"1009_CR11","doi-asserted-by":"publisher","first-page":"760","DOI":"10.1111\/cbdd.13486","volume":"93","author":"S Talaei","year":"2019","unstructured":"Talaei S, Mellatyar H, Asadi A, Akbarzadeh A, Sheervalilou R, Zarghami N. Spotlight on 17-AAG as an Hsp90 inhibitor for molecular targeted cancer treatment. Chem Biol Drug Des. 2019;93(5):760\u201386.","journal-title":"Chem Biol Drug Des"},{"issue":"12","key":"1009_CR12","doi-asserted-by":"publisher","first-page":"799","DOI":"10.1038\/s41419-023-06337-3","volume":"14","author":"M Vogt","year":"2023","unstructured":"Vogt M, Dienstbier N, Schliehe-Diecks J, Scharov K, Tu JW, Gebing P, Hogenkamp J, Bilen BS, Furlan S, Picard D, et al. Co-targeting HSP90 alpha and CDK7 overcomes resistance against HSP90 inhibitors in BCR-ABL1\u2009+\u2009leukemia cells. Cell Death Dis. 2023;14(12):799.","journal-title":"Cell Death Dis"},{"key":"1009_CR13","doi-asserted-by":"publisher","first-page":"115207","DOI":"10.1016\/j.bcp.2022.115207","volume":"204","author":"JC Ko","year":"2022","unstructured":"Ko JC, Chen JC, Hsieh JM, Tseng PY, Chiang CS, Liu LL, Chien CC, Huang IH, Chang QZ, Mu BC, et al. Heat shock protein 90 inhibitor 17-AAG down-regulates thymidine phosphorylase expression and potentiates the cytotoxic effect of tamoxifen and erlotinib in human lung squamous carcinoma cells. Biochem Pharmacol. 2022;204:115207.","journal-title":"Biochem Pharmacol"},{"issue":"2","key":"1009_CR14","doi-asserted-by":"publisher","first-page":"240","DOI":"10.1016\/j.bbcan.2019.01.002","volume":"1871","author":"K Kryeziu","year":"2019","unstructured":"Kryeziu K, Bruun J, Guren TK, Sveen A, Lothe RA. Combination therapies with HSP90 inhibitors against colorectal cancer. Biochim Biophys Acta Rev Cancer. 2019;1871(2):240\u20137.","journal-title":"Biochim Biophys Acta Rev Cancer"},{"issue":"5","key":"1009_CR15","doi-asserted-by":"publisher","first-page":"442","DOI":"10.1007\/s12272-024-01494-1","volume":"47","author":"Y Liu","year":"2024","unstructured":"Liu Y, Li C, Liu H, Tan S. Combination therapy involving HSP90 inhibitors for combating cancer: an overview of clinical and preclinical progress. Arch Pharm Res. 2024;47(5):442\u201364.","journal-title":"Arch Pharm Res"},{"issue":"12","key":"1009_CR16","doi-asserted-by":"publisher","first-page":"1636","DOI":"10.1038\/nm.2536","volume":"17","author":"P D\u2019Arcy","year":"2011","unstructured":"D\u2019Arcy P, Brnjic S, Olofsson MH, Fryknas M, Lindsten K, De Cesare M, Perego P, Sadeghi B, Hassan M, Larsson R, et al. Inhibition of proteasome deubiquitinating activity as a new cancer therapy. Nat Med. 2011;17(12):1636\u201340.","journal-title":"Nat Med"},{"issue":"9\u201310","key":"1009_CR17","doi-asserted-by":"publisher","first-page":"826","DOI":"10.1007\/s10495-019-01561-9","volume":"24","author":"B Sha","year":"2019","unstructured":"Sha B, Chen X, Wu H, Li M, Shi J, Wang L, Liu X, Chen P, Hu T, Li P. Deubiquitylatinase inhibitor b-AP15 induces c-Myc-Noxa-mediated apoptosis in esophageal squamous cell carcinoma. Apoptosis. 2019;24(9\u201310):826\u201336.","journal-title":"Apoptosis"},{"key":"1009_CR18","doi-asserted-by":"publisher","first-page":"291","DOI":"10.1016\/j.bcp.2018.08.039","volume":"156","author":"X Zhang","year":"2018","unstructured":"Zhang X, Pellegrini P, Saei AA, Hillert EK, Mazurkiewicz M, Olofsson MH, Zubarev RA, D\u2019Arcy P, Linder S. The deubiquitinase inhibitor b-AP15 induces strong proteotoxic stress and mitochondrial damage. Biochem Pharmacol. 2018;156:291\u2013301.","journal-title":"Biochem Pharmacol"},{"issue":"12","key":"1009_CR19","doi-asserted-by":"publisher","first-page":"2537","DOI":"10.1038\/s41401-023-01136-0","volume":"44","author":"W Ding","year":"2023","unstructured":"Ding W, Wang JX, Wu JZ, Liu AC, Jiang LL, Zhang HC, Meng Y, Liu BY, Peng GJ, Lou EZ, et al. Targeting proteasomal deubiquitinases USP14 and UCHL5 with b-AP15 reduces 5-fluorouracil resistance in colorectal cancer cells. Acta Pharmacol Sin. 2023;44(12):2537\u201348.","journal-title":"Acta Pharmacol Sin"},{"key":"1009_CR20","doi-asserted-by":"publisher","first-page":"387","DOI":"10.1016\/j.omto.2022.08.004","volume":"26","author":"PM Chow","year":"2022","unstructured":"Chow PM, Dong JR, Chang YW, Kuo KL, Lin WC, Liu SH, Huang KH. The UCHL5 inhibitor b-AP15 overcomes cisplatin resistance via suppression of cancer stemness in urothelial carcinoma. Mol Ther Oncolytics. 2022;26:387\u201398.","journal-title":"Mol Ther Oncolytics"},{"issue":"2","key":"1009_CR21","doi-asserted-by":"publisher","first-page":"440","DOI":"10.1158\/0008-5472.CAN-09-1947","volume":"70","author":"TC Chou","year":"2010","unstructured":"Chou TC. Drug combination studies and their synergy quantification using the Chou-Talalay method. Cancer Res. 2010;70(2):440\u20136.","journal-title":"Cancer Res"},{"issue":"43","key":"1009_CR22","doi-asserted-by":"publisher","first-page":"43697","DOI":"10.1021\/acsomega.4c06152","volume":"9","author":"C Xu","year":"2024","unstructured":"Xu C, Chen Y, Zhou Z, Yan Y, Fu W, Zou P, Ni D. ML385, an Nrf2 Inhibitor, synergically enhanced Celastrol triggered Endoplasmic reticulum stress in lung cancer cells. ACS Omega. 2024;9(43):43697\u2013705.","journal-title":"ACS Omega"},{"issue":"1","key":"1009_CR23","doi-asserted-by":"publisher","first-page":"249","DOI":"10.7150\/ijbs.86160","volume":"20","author":"P Zheng","year":"2024","unstructured":"Zheng P, Xia Y, Shen X, Lu H, Chen Y, Xu C, Qiu C, Zhang Y, Zou P, Cui R, et al. Combination of TrxR1 inhibitor and lenvatinib triggers ROS-dependent cell death in human lung cancer cells. Int J Biol Sci. 2024;20(1):249\u201364.","journal-title":"Int J Biol Sci"},{"key":"1009_CR24","doi-asserted-by":"publisher","first-page":"101084","DOI":"10.1016\/j.redox.2018.101084","volume":"25","author":"US Srinivas","year":"2019","unstructured":"Srinivas US, Tan BWQ, Vellayappan BA, Jeyasekharan AD. ROS and the DNA damage response in cancer. Redox Biol. 2019;25:101084.","journal-title":"Redox Biol"},{"key":"1009_CR25","doi-asserted-by":"crossref","unstructured":"Davalli P, Marverti G, Lauriola A, D\u2019Arca D. targeting oxidatively induced DNA damage response in cancer: opportunities for novel cancer therapies. Oxid Med Cell Longev 2018;2389523.","DOI":"10.1155\/2018\/2389523"},{"issue":"10","key":"1009_CR26","doi-asserted-by":"publisher","first-page":"648","DOI":"10.1038\/s41419-023-06154-8","volume":"14","author":"S Liu","year":"2023","unstructured":"Liu S, Yao S, Yang H, Liu S, Wang Y. Autophagy: regulator of cell death. Cell Death Dis. 2023;14(10):648.","journal-title":"Cell Death Dis"},{"issue":"3","key":"1009_CR27","doi-asserted-by":"publisher","first-page":"1093","DOI":"10.7150\/ijbs.85443","volume":"20","author":"TM Chang","year":"2024","unstructured":"Chang TM, Chi MC, Chiang YC, Lin CM, Fang ML, Lee CW, Liu JF, Kou YR. Promotion of ROS-mediated apoptosis, G2\/M arrest, and autophagy by naringenin in non-small cell lung cancer. Int J Biol Sci. 2024;20(3):1093\u2013109.","journal-title":"Int J Biol Sci"},{"issue":"9","key":"1009_CR28","doi-asserted-by":"publisher","first-page":"3636","DOI":"10.7150\/ijbs.71870","volume":"18","author":"TG Mhone","year":"2022","unstructured":"Mhone TG, Chen MC, Kuo CH, Shih TC, Yeh CM, Wang TF, Chen RJ, Chang YC, Kuo WW, Huang CY. Daidzein synergizes with gefitinib to induce ROS\/JNK\/c-Jun activation and inhibit EGFR-STAT\/AKT\/ERK pathways to enhance lung adenocarcinoma cells chemosensitivity. Int J Biol Sci. 2022;18(9):3636\u201352.","journal-title":"Int J Biol Sci"},{"issue":"8","key":"1009_CR29","doi-asserted-by":"publisher","first-page":"485","DOI":"10.21037\/atm-22-1298","volume":"10","author":"Q Chen","year":"2022","unstructured":"Chen Q, Hou Y, Li D, Ding Z, Xu X, Hao B, Xia Q, Li M, Fan L. Berberine induces non-small cell lung cancer apoptosis via the activation of the ROS\/ASK1\/JNK pathway. Ann Transl Med. 2022;10(8):485.","journal-title":"Ann Transl Med"},{"issue":"3","key":"1009_CR30","doi-asserted-by":"publisher","first-page":"448","DOI":"10.1158\/1535-7163.MCT-15-0778","volume":"15","author":"CY Wang","year":"2016","unstructured":"Wang CY, Guo ST, Wang JY, Liu F, Zhang YY, Yari H, Yan XG, Jin L, Zhang XD, Jiang CC. Inhibition of HSP90 by AUY922 preferentially kills mutant KRAS colon cancer cells by activating Bim through ER stress. Mol Cancer Ther. 2016;15(3):448\u201359.","journal-title":"Mol Cancer Ther"},{"key":"1009_CR31","doi-asserted-by":"publisher","first-page":"115409","DOI":"10.1016\/j.bcp.2022.115409","volume":"208","author":"E Onay Ucar","year":"2023","unstructured":"Onay Ucar E, Sengelen A, Mertoglu Kamali E. Hsp27, Hsp60, Hsp70, or Hsp90 depletion enhances the antitumor effects of Resveratrol via oxidative and ER stress response in human glioblastoma cells. Biochem Pharmacol. 2023;208:115409.","journal-title":"Biochem Pharmacol"},{"issue":"3","key":"1009_CR32","first-page":"209","volume":"71","author":"H Sung","year":"2021","unstructured":"Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, Bray F. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021;71(3):209\u201349.","journal-title":"CA Cancer J Clin"},{"issue":"Pt 1","key":"1009_CR33","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1016\/j.semcancer.2017.11.019","volume":"52","author":"L Osmani","year":"2018","unstructured":"Osmani L, Askin F, Gabrielson E, Li QK. Current WHO guidelines and the critical role of immunohistochemical markers in the subclassification of non-small cell lung carcinoma (NSCLC): moving from targeted therapy to immunotherapy. Semin Cancer Biol. 2018;52(Pt 1):103\u20139.","journal-title":"Semin Cancer Biol"},{"issue":"4","key":"1009_CR34","doi-asserted-by":"publisher","first-page":"555","DOI":"10.1016\/j.soc.2020.06.009","volume":"29","author":"B Sepesi","year":"2020","unstructured":"Sepesi B, Cascone T, Chun SG, Altan M, Le X. Emerging therapies in thoracic Malignancies-Immunotherapy, targeted therapy, and T-Cell therapy in Non-Small cell lung cancer. Surg Oncol Clin N Am. 2020;29(4):555\u201369.","journal-title":"Surg Oncol Clin N Am"},{"key":"1009_CR35","doi-asserted-by":"publisher","first-page":"103417","DOI":"10.1016\/j.critrevonc.2021.103417","volume":"164","author":"J Kaur","year":"2021","unstructured":"Kaur J, Elms J, Munn AL, Good D, Wei MQ. Immunotherapy for non-small cell lung cancer (NSCLC), as a stand-alone and in combination therapy. Crit Rev Oncol Hematol. 2021;164:103417.","journal-title":"Crit Rev Oncol Hematol"},{"issue":"11","key":"1009_CR36","doi-asserted-by":"publisher","first-page":"1478","DOI":"10.1016\/j.jtho.2023.08.011","volume":"18","author":"Y Li","year":"2023","unstructured":"Li Y, Juergens RA, Finley C, Swaminath A. Current and future treatment options in the management of stage III NSCLC. J Thorac Oncol. 2023;18(11):1478\u201391.","journal-title":"J Thorac Oncol"},{"issue":"9","key":"1009_CR37","doi-asserted-by":"publisher","first-page":"5123","DOI":"10.21037\/tcr-24-637","volume":"13","author":"L Kuang","year":"2024","unstructured":"Kuang L, Wang P, Zhou L, Li Y. Strategies and influencing factors for the treatment of advanced non-small cell lung cancer based on epidermal growth factor receptor tyrosine kinase inhibitors: a narrative review. Transl Cancer Res. 2024;13(9):5123\u201340.","journal-title":"Transl Cancer Res"},{"key":"1009_CR38","doi-asserted-by":"crossref","unstructured":"Zielinski P, Stepien M, Chowaniec H, Kalyta K, Czerniak J, Borowczyk M, Dwojak E, Mroczek M, Dworacki G, Slubowska A et al. Resistance in lung cancer immunotherapy and how to overcome it: insights from the genetics perspective and combination therapies approach. Cells 2025;14(8).","DOI":"10.3390\/cells14080587"},{"key":"1009_CR39","doi-asserted-by":"crossref","unstructured":"Ashrafi A, Akter Z, Modareszadeh P, Modareszadeh P, Berisha E, Alemi PS, Chacon Castro MDC, Deese AR, Zhang L. Current landscape of therapeutic resistance in lung cancer and promising strategies to overcome resistance. Cancers (Basel) 2022;14(19).","DOI":"10.3390\/cancers14194562"},{"key":"1009_CR40","doi-asserted-by":"crossref","unstructured":"Li ZN, Luo Y. HSP90 inhibitors and cancer: prospects for use in targeted therapies (Review). Oncol Rep 2023;49(1).","DOI":"10.3892\/or.2022.8443"},{"issue":"1","key":"1009_CR41","doi-asserted-by":"publisher","first-page":"105","DOI":"10.7150\/thno.63788","volume":"12","author":"HJ Lee","year":"2022","unstructured":"Lee HJ, Min HY, Yong YS, Ann J, Nguyen CT, La MT, Hyun SY, Le HT, Kim H, Kwon H, et al. A novel C-terminal heat shock protein 90 inhibitor that overcomes STAT3-Wnt-beta-catenin signaling-mediated drug resistance and adverse effects. Theranostics. 2022;12(1):105\u201325.","journal-title":"Theranostics"},{"key":"1009_CR42","doi-asserted-by":"publisher","first-page":"155317","DOI":"10.1016\/j.phymed.2023.155317","volume":"128","author":"X Chen","year":"2024","unstructured":"Chen X, Zhu N, Wu Y, Zhang Y, Zhang Y, Jin K, Zhou Z, Chen G, Wang J. Withaferin A, a natural thioredoxin reductase 1 (TrxR1) inhibitor, synergistically enhances the antitumor efficacy of Sorafenib through ROS-mediated ER stress and DNA damage in hepatocellular carcinoma cells. Phytomedicine. 2024;128:155317.","journal-title":"Phytomedicine"},{"issue":"1\u20132","key":"1009_CR43","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1007\/s10495-021-01697-7","volume":"27","author":"Y Bellizzi","year":"2022","unstructured":"Bellizzi Y, Anselmi Relats JM, Cornier PG, Delpiccolo CML, Mata EG, Cayrol F, Cremaschi GA, Blank VC, Roguin LP. Contribution of Endoplasmic reticulum stress, MAPK and PI3K\/Akt pathways to the apoptotic death induced by a penicillin derivative in melanoma cells. Apoptosis. 2022;27(1\u20132):34\u201348.","journal-title":"Apoptosis"},{"key":"1009_CR44","doi-asserted-by":"crossref","unstructured":"Kwak AW, Choi JS, Lee MH, Oh HN, Cho SS, Yoon G, Liu K, Chae JI, Shim JH. Retrochalcone echinatin triggers apoptosis of esophageal squamous cell carcinoma via ROS- and ER Stress-Mediated Signaling Pathways. Molecules 2019; 24(22).","DOI":"10.3390\/molecules24224055"},{"key":"1009_CR45","doi-asserted-by":"publisher","first-page":"153824","DOI":"10.1016\/j.phymed.2021.153824","volume":"94","author":"Z Liu","year":"2022","unstructured":"Liu Z, Wu X, Dai K, Li R, Zhang J, Sheng D, Lee SM, Leung GP, Zhou GC, Li J. The new Andrographolide derivative AGS-30 induces apoptosis in human colon cancer cells by activating a ROS-dependent JNK signalling pathway. Phytomedicine. 2022;94:153824.","journal-title":"Phytomedicine"},{"key":"1009_CR46","doi-asserted-by":"crossref","unstructured":"Zhang T, Xu C, Zheng P, Zhang X, Qiu C, Wu F, Chen J, Xiao Z, Zhu J, Zhang J, et al. Glaucocalyxin B attenuates ovarian cancer cell growth and cisplatin resistance in vitro via activating oxidative stress. Oxid Med Cell Longev 2022:6324292.","DOI":"10.1155\/2022\/6324292"},{"issue":"12","key":"1009_CR47","doi-asserted-by":"publisher","first-page":"931","DOI":"10.1038\/nrd4002","volume":"12","author":"C Gorrini","year":"2013","unstructured":"Gorrini C, Harris IS, Mak TW. Modulation of oxidative stress as an anticancer strategy. Nat Rev Drug Discov. 2013;12(12):931\u201347.","journal-title":"Nat Rev Drug Discov"},{"issue":"13","key":"1009_CR48","doi-asserted-by":"publisher","first-page":"e110031","DOI":"10.15252\/embj.2021110031","volume":"41","author":"RC Russell","year":"2022","unstructured":"Russell RC, Guan KL. The multifaceted role of autophagy in cancer. EMBO J. 2022;41(13):e110031.","journal-title":"EMBO J"},{"issue":"1","key":"1009_CR49","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1186\/s12943-024-02217-2","volume":"24","author":"P Zhao","year":"2025","unstructured":"Zhao P, Yin S, Qiu Y, Sun C, Yu H. Ferroptosis and pyroptosis are connected through autophagy: a new perspective of overcoming drug resistance. Mol Cancer. 2025;24(1):23.","journal-title":"Mol Cancer"}],"container-title":["BMC Pharmacology and Toxicology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s40360-025-01009-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s40360-025-01009-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s40360-025-01009-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,29]],"date-time":"2025-10-29T03:02:30Z","timestamp":1761706950000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcpharmacoltoxicol.biomedcentral.com\/articles\/10.1186\/s40360-025-01009-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10,28]]},"references-count":49,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["1009"],"URL":"https:\/\/doi.org\/10.1186\/s40360-025-01009-8","relation":{},"ISSN":["2050-6511"],"issn-type":[{"type":"electronic","value":"2050-6511"}],"subject":[],"published":{"date-parts":[[2025,10,28]]},"assertion":[{"value":"16 April 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 September 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 October 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics and consent to participate declarations"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"177"}}